Neoadjuvant immunotherapy for locally advanced melanoma
MS Pelster, RN Amaria - Current treatment options in oncology, 2020 - Springer
Opinion statement Patients with clinical stage III melanoma, defined as palpable lymph
nodes with or without in-transit metastases, have poor prognosis even with recent advances …
nodes with or without in-transit metastases, have poor prognosis even with recent advances …
Neoadjuvant Immunotherapy for Locally Advanced Melanoma
MS Pelster, RN Amaria - Current treatment options in …, 2020 - pubmed.ncbi.nlm.nih.gov
Patients with clinical stage III melanoma, defined as palpable lymph nodes with or without in-
transit metastases, have poor prognosis even with recent advances with targeted and …
transit metastases, have poor prognosis even with recent advances with targeted and …
Neoadjuvant Immunotherapy for Locally Advanced Melanoma
MS Pelster, RN Amaria - Current treatment …, 2020 - mdanderson.elsevierpure.com
Patients with clinical stage III melanoma, defined as palpable lymph nodes with or without in-
transit metastases, have poor prognosis even with recent advances with targeted and …
transit metastases, have poor prognosis even with recent advances with targeted and …
Neoadjuvant Immunotherapy for Locally Advanced Melanoma.
MS Pelster, RN Amaria - Current Treatment Options in Oncology, 2020 - europepmc.org
Patients with clinical stage III melanoma, defined as palpable lymph nodes with or without in-
transit metastases, have poor prognosis even with recent advances with targeted and …
transit metastases, have poor prognosis even with recent advances with targeted and …